Keyword Index for Volume 96


13-cis-retinoic acid 424
14-3-3 296
19F-MRS 758
1H HRMAS NMR 1684
2-methoxyoestradiol 1368
4-phenylbutyrate 73
5-fluorouracil 21, 551, 701, 1043
5-FU and antifolates 769
abortion 1450
ABT-737 600
accident 752
acute leukaemia 535
adenocarcinoma 519
adenocarcinoma of the cardia 1767
adenocarcinoma of the oesophagus 1767
adenovirus 1871
adhesion 1699
adjuvant chemotherapy 1170, 1409, 1633
adjuvant treatment 1656
ADRA1B 383
advanced colorectal cancer 38
advanced non-small cell lung cancer 1644
aetiology 832
age–period–cohort pattern analysis 1767
AIP 352
Akt 445, 993, 1047
albumin 891
alcohol 821, 1469
allelic imbalance 499
amphiregulin 1569
amplification 474
anaplastic carcinoma 1549
androgen receptor 970, 1595
aneuploidy 1908
angiogenesis 1083, 1092, 1735, 1888
angiogenesis inhibitors 189, 1159, 1368, 1735, 1788
annexin V 928
anoikis 993
anthracyclines 226
anti-inflammatory agents 937
antimetabolites 61
antitumour activity 1204
antitumour immunity 617
antitumour response 1072
antivascular effect 1532
APC 631
APC mutations 1729
apoptosis 196, 231, 450, 575, 583, 639, 918, 928, 944, 1062, 1083, 1204, 1425, 1532, 1579, 1659
array analysis 762
array CGH 373
ASPP 196
atypical hyperplasia 1253
β-adrenergic receptor kinase (BARK1, GRK2) protein phosphatase (PP1α, PP2A) 82
B23 477
Barrett's oesophagus 1377, 1767
basal cell carcinoma 523
BAT26 1409
BAX 1409
BBD 110
Bcl-2 1409, 1540, 1659
Bcl-2 inhibitor 600
bendamustine 1692
benign prostatic hyperplasia 137, 1475
benign prostatic hypertrophy 523
BHD 336
Big Blue 660
bile duct carcinoma 896
biliary tract carcinoma 896
biomarkers 118, 189, 362, 445, 857
birth order 1755
birth weight 134
bisphosphonates 255, 1526
bladder cancer 169, 1711
bladder tumours 762
Bmi-1 126
body mass index 49, 510, 845, 1457
body site 832
bone marrow 654, 1723
bone metastasis 1526
bone resorption 1716
borderline histology 1253
BRAF 445, 1549
brain 6
brain tumour 1293
BRCA1 11, 118, 1335
BRCA2 11, 1335
breakthrough pain 1828
breast cancer 11, 104, 134, 157, 162, 341, 352, 575, 639, 646, 654, 744, 801, 836, 841, 850, 903, 1001, 1092, 1135, 1197, 1204, 1258, 1368, 1404, 1436, 1462, 1504, 1520, 1526, 1625, 1743, 1747, 1796, 1802, 1808
breast feeding 815, 1450
breast neoplasms 1025, 1139, 1253
burden of disease 1484
C. albicans 137
Ca 110
CA125 1335
CA19-9 1650
cadherin 1
cancer cachexia 1216
cancer genetics 391
cancer immunotherapy 600
cancer networks 886
cancer plan 886
cancer registration 140, 1760
cancer registries 1493, 1743
cancer research agenda 875
cancer screening 623
cancer stem cell 201, 1020
capecitabine 912, 1348, 1514
capillaries 1788
carbonic anhydrase (CA IX) 104
carboplatin 559, 725
carcinoma 1425
cardia cancer 1272
cardiomyocytes 1667
cardioprotection 226
cardiotoxicity 937
cardiovascular disease 1747
care interval resolution 162
case–control studies 815, 1457
caspase-3 1659
caspase-7 944
caspases 450, 583
CBP 183
CCK-2R 1855
CD 8 lymphocytes 67
CD133 radial glia 6
CD326 417
CEACAM1 609
cell adhesion 1394
cell cycle 639
cell proliferation 477
cellular aging 1908
centrifugal assay for cell adhesion 1246
cerebral metastases 44
cervical cancer 143, 321, 591, 738, 1107, 1320, 1480
cervical intraepithelial neoplasia 738, 1234, 1419
cervical screening 1419
cetuximab 206
CGH 1237
Charlson comorbidity score 1462
chemiosensitivity 1358
chemoembolisation 49
chemoprevention 248
chemoradiation 1183, 1353
chemoradiotherapy 432, 912, 1650
chemoresistance 1699
chemosensitivity 241, 960
chemotherapy 44, 708, 732, 886, 1043, 1052, 1183, 1343, 1442, 1639, 1644, 1808
childhood cancer 815
childhood cancer survivors 1439
childhood leukaemia 1265
children 226, 667, 1147
China 172, 1554
cholangiocarcinoma 896
chromatin immunoprecipitation 1284
chromophobe renal cell carcinoma 336
chromosomal instability 960
chromosomal stability 1908
cigarette smoking 821
CIN2/3 1320
circulating nucleic acids 681
CIS 110
cisplatin 277
CK20 1711
clear cell carcinoma 290, 1613
clearance 1419
clinic 1625
clinical pharmacology 424, 725
clinical trials 189, 857, 1159
clodronate 1796
c-Met 329
CNS tumours 815
codon 72 1302
cohort 845, 1469
cohort studies 169, 510, 1457, 1755
colon cancer 61, 213, 701, 769
colon carcinoma 1409
colon carcinoma cells 21
colon carcinoma; uptake 1684
colonic neoplasm 1030
colonoscopy 828
colorectal 206, 692
colorectal cancer 140, 218, 231, 510, 660, 793, 821, 828, 986, 1112, 1118, 1166, 1329, 1750
colorectal liver metastases 222
colorectal metastases 1037
colorectal neoplasms 1605
colorectal tumours 352
combination studies 231
combined effects 255
combined modality 1183
combined modality therapy 1823
comparative genomic hybridisation 341, 667
complement system 67
consultation 875
controlled trial 744
core needle biopsy 1253
corpus cancer 1272
cost-effectiveness 206
CPT-11 38
C-reactive protein 222, 891
Cripto Mab 918
cryotherapy 738
CT chest 882
CT-26 1684
CTL 1072
cutaneous B-cell lymphoma (CBCL) 1540
CXCR4 485
cyclin-dependent kinase inhibitor 29
cyclooxygenase-2 575
CYP26 1675
cytoplasmic 970
cytosine deaminase 758
cytoskeleton 1
day 1+2 schedule 1692
DDR1 808
DDR2 808
death mechanisms 928
decatenation checkpoint 201
deletion 357
deliberate self-harm 752
deoxycytidine kinase 457
desmocollin 1783
desmoglein 1783
desmosome 1783
detection 1802
DHHC9 1896
diabetes 507, 1747
diagnosis 157, 535, 1197, 1329
diagnostic accuracy 1107
Dickkopf-1 (DKK1) 646
diet 248
differentiation 1204
disease susceptibility 523
distress 868
DNA double strand break 1707
DNA methylation 383, 1605
DNA mismatch repair 1605
DNA repair 118
DNA replication licensing 1384
DNA virus 137
DNA-strand breaks 231
docetaxel 432
dosing 424
doxorubicin 450, 937, 1520, 1667
drug evaluation 269
drug metabolism 424
dsRNA-dependent protein kinase 1216
dual targeting 952
ductal carcinoma 1404
dynamic contrast-enhanced magnetic resonance imaging 189
dysadherin 1404
dyskeratosis congenita 1020
dysplasia 492
early detection 738
early gastric cancer (EGC) 89
early-onset breast cancer 712, 1633
EBV 623
ED-B 1862
eEF1A2 1613
EGF-receptor signalling 408
EGFR 110, 284, 762, 793, 952, 1047, 1166, 1246, 1569
EGFR mutations 1191
EGR1 762
elapsed times 162
elderly patients 1197, 1823
EMT 1, 1783
endocrine tumour 49
endometrial cancer 134, 591, 1450, 1639, 1747
endoplasmic reticulum stress 944, 1062
endoscopic submucosal dissection (ESD) 89
endoscopy 492
England 1484
England and Wales 1135
environment 1740
EpCAM 417, 1013
ependymoma 6
EphB4 1083
epidemiological trends 1767
epidemiology 151, 157, 832, 1234, 1436, 1439, 1484
epidermal growth factor 1569
epidermal growth factor receptor (EGFR) inhibitor 1191
epigenetics 183
epirubicin 1043, 1633
epithelial ovarian carcinoma 314
epithelial–mesenchymal transition 1246
ER 583
erlotinib 857, 952
erythropoietin 692
ESFT 1914
Ewing's sarcoma 1716
exposure patterns 523
expression 1237
extragonadal 667
faecal occult blood tests 218, 1750
familial breast cancer 1740
familial risk 1272
fascin 1118
E-cadherin 1404
fenretinide 1062
fertility and premature ovarian failure 1808
FGF 1544
FGFR4 1904
FHIT 110
fibrosis 1001
fluoropyrimidines 61
FOBT 218
follow up 1625
formaldehyde 1667
Foscan® 944
FOXp3 1879
fumarate hydratase 403
γ-inulin 67
G2 checkpoint 201
gallbladder cancer 1457
gallbladder carcinoma 896
gastric and intestinal marker 631
gastric cancer 95, 172, 277, 383, 1043, 1272, 1723
gastric carcinoma 631
gastric cardia 631
gastrin 464
gastroenteropancreatic tract 1178
gastrointestinal cancer 464
gastrointestinal stromal tumours (GIST) 776, 1656, 1834
gastro-oesophageal junction tumours 95
gefitinib 284, 762, 857, 1047, 1191
gemcitabine 73, 896
gemcitabine resistance 457
geminin 1384
gene amplification 1258
gene expression 1258
gene expression profiling 535
gene promoter methylation 1278
gene regulation 362
gene therapy 758, 1871
genetic assessment 391
genetic models of carcinogenesis 248
genetic testing 718
genomic instability 660
geographical incidence 1760
germ cell 667
germ cell tumour 357
germline 1265
gestational trophoblastic neoplasia 732
GIST 1834
glioblastoma multiforme 474, 1293
glutathione-S-transferase pi 1587
Gly388Arg polymorphism 1904
gonadal 667
gonorrhoea 169
Grb7 1520
gr/gr 357
GSK-3 1595
G-quadruplex 1223
H. felis 1855
HA14-1 600
HADS 868
HDAC inhibitor 73
head and neck cancer 1469
head and neck carcinoma 1569
health services 701
Helicobacter pylori 172, 1324
heparanase 1544
hepatitis B virus 1127
hepatitis C virus 1127
hepatocellular carcinoma 477, 1127
HER receptors 801
HER2 654
HER2/neu 485
hereditary leiomyomatosis and renal cell cancer 403
hereditary nonpolyposis 1605
heredity 1740
heterotypic cell–cell adhesion 1246
HHV8 183
HIF-1α 95, 1377
HIF-2α 1377
high LET radiation 1707
high-grade gliomas 1047, 1560
histology, twin births 1433
histone acetylation 1667
histone modifications 183
HMGA1 993
HNF1β 336
Hodgkin's lymphoma 1442
hollow fibre assay 61
hormonal manipulation 1343
hormone 151, 845
HPA 609
HPV 514, 1554
HPV types 1480
HPV16/18 L1 VLPs 1320
HS 1544
HSULF-1 1544
human 1358
human immunodeficiency virus 1480
human kallikreins 6 362
human papillomavirus 143, 1234, 1419, 1480
hypoxia 104, 1302, 1377, 1888
hypoxia-inducible factor 403, 1284
hypoxia-inducible factor-1 (HIF-1) 1871
hypoxia-response element (HRE) 1871
ICRF-193 201
IDO 1879
IGF1 genotype 712
IL-6 gene 474
image analysis 189, 329
imatinib 1656
imatinib mesylate 1834
immune surveillance 1849
immunocytochemistry 329, 1107
immunohistochemistry 306, 314, 485, 1118, 1896
immunorecognition 1072
immunotherapy 1013, 1293
in vivo pharmacodynamics 61
incidence 818, 1772
incidence rates 1743
indisulam 559
individual patient data meta-analysis 1170
individualized chemotherapy 241
individualized therapy 857
infection 169
inflammation 169, 937
inflammatory response 222
inhibition 1216
InsGas 1855
insulin-like growth factor binding protein 3 1587
integration 1554
integrin 1394
interfering RNA 464
international comparisons 1493
intestinal metaplasia 383
intravenous morphine 1828
invasion 1, 1112
IP-10 1735
irinotecan 21, 38, 439, 546, 551, 912, 1514
isotretinoin 424
keratinocytes 126
Ki-67 445, 970, 1504, 1711
kidney cancer 403, 646
kidney neoplasms 845
KIT 1656
KRAS 631, 1166
KSHV 183
L1 609
L19-SIP 1862
LASP-1 296
leucovorin 1043
lipopolysaccaride 262
liver function tests 1178
liver metastases 1112
liver resection 1037
lobular carcinoma 1404
locally advanced rectal cancer 551, 912
LOH 499
lomustine 44
long-term 1135
long-term outcome 1324
low dose 1707
low dose rate 1707
Lugol staining 492
lung cancer 519, 646, 808, 886, 1052, 1278, 1904
lymph node 321
lymph node resection 1817
lymphangiogenesis 541, 575, 1092
macrophage 1716
magnesium 510
malignancies 477, 1101
malignant melanoma 832
mammography 157
MAP kinase 445
mass screening 56
mathematical model 143
Matrigel plug assay 1368
mayo regime 701
MBD4 660
Mcm2 1384, 1711
MDR 918
meat 1139
medication review 744
meeting report 417
MEK5/ERK5 1384
melanoma 44, 445, 1072, 1772, 1879
melanoma model 609
menopause 841
meta-analysis 1127, 1457, 1504, 1796
metachronous recurrent cancer 89
metalloproteinase 783
metaplastic 1855
metastases 1723
metastasis 262, 541, 903, 1394
metastatic colorectal cancer 439, 546
methylation 183, 1587
methylcholanthrene 1849
MGMT 960
microarray analysis 535
microarrays 341, 1155, 1896
microcirculation 692
micrometastases 321
micrometastasis 654
microsatellite instability 89, 631, 1409, 1605, 1896
microtubule 1532
microvessel density 1112
migration 296, 1560
minichromosome maintenance proteins 1107
minisatellite 1265
mitochondrial membrane potential 928
mitomycin 1052
mitotic arrest 1532
MLPA 1914
MMP 903
modelling 514
molecular markers 1166
molecular profiling 321
monoclonal antibody 408
monoHER 450, 937
mortality 1747, 1772
Motzer 567
mouse tumours 67
mTOR 952
mucosa-associated lymphoid tissue lymphoma 1324
multidrug resistance 1579
multiparity 712
multiple colorectal adenoma 1729
multiple primaries 529
muscle protein degradation 1216
muscle protein synthesis 1216
mutation 336, 808, 1166, 1265, 1549, 1656
mutation frequency 660
MYC 82
MYH/MUTYH mutations 1729
Nɛ-(carboxymethyl)lysine 937
nasopharyngeal carcinoma 617
NCAM 1699
necrosis 928
neoadjuvant chemotherapy 341, 1037
neoplasm staging 1030
neoplasms 667
neovascularization pathologic 980
neuroblastoma 1675, 1699
neuro-ectodermal tumours 1062
neuroendocrine carcinomas 1178
neuroendocrine tumours 1343
neutralising antibody 1320
NK cells 1839
NKT cells 600
(non) tumour cells 450
non-phosphorylated peptide 1520
nonseminoma 529
non-small cell lung cancer 886, 1052, 1191, 1569
NPC 623
nucleophosmin 477
nucleoside transporter 457
number of sibling 1755
nurse's role 1057
obesity 1457
oesophageal cancer 172, 432, 708, 1348, 1823
oesophageal squamous cell carcinoma 1554
oesophagitis 492
oestrogen receptor 1595
offspring's gender 1436
oncogenic virus 183
opioids 1828
oral cancer 126, 1425
oral carcinoma 818
oro-pharyngeal carcinoma 818
osteoclast 1716
osteosarcoma 255
OTFC 1828
ovarian cancer 11, 151, 290, 296, 362, 485, 850, 1083, 1433, 1544, 1747, 1817
ovarian carcinoma 306, 1335
ovarian neoplasms 1908
ovarian reserve 1808
ovarian tumour 1613
oxaliplatin 38, 231, 439, 546, 1043, 1348
oxygenation 692
p14ARF 1914
p16 1914
p16INK4A 126, 306
p21Cip1 970
p300 183
p53 196, 277, 631, 769, 1302, 1425
p53 mutation 492
p53/BAX pathway 1409
p53-response element 1579
paclitaxel 241
paediatric cancer 1493
paediatrics 725
PALGA 1234
pancreatic adenocarcinoma 993
pancreatic cancer 373, 457, 507, 1183, 1353, 1358, 1650
pancreatic carcinoma 73
PAP 352
papillary carcinoma 1549
papillary thyroid cancer 16
parity 845
participatory 875
paternal/maternal lineage 1740
PCNA 110, 477
PDGFRA 1656
PDT 1839
penetrance 11
peripheral blood 1723
P-glycoprotein 918
pharmacokinetics 559, 1692
pharmacy 744
phase I 21, 29, 559, 1353, 1692
phase II study 432, 864
phospholipids 1684
photodynamic therapy 67, 944
Physiology Score 213
PI3K pathway 1595
Pidd 1425
pituitary adenoma 352
PL 583
plakoglobin 1783
plasma/serum DNA 681
plasma/serum RNA 681
platinum compounds 896
platinum–DNA adducts 725
podoplanin 1
polycomb 126
polymorphism 336, 1302
population-based 1462, 1475, 1493, 1743
POSSUM 213
postmenopausal 151
post-treatment parenthood 1442
potentiation 269
pRb 306
precursor 492
predictive 1155
predictive marker 457
predictive value 1253
pre-eclampsia 1436
pre-malignant 1855
preoperative chemoradiation 551
preoperative chemoradiotherapy 1498
prevalence 868
prevention 828
primary brain lymphoma 864
primary breast cancer 891
primary health care 1057
primary prevention 1057
primary tumour cells 241
priorities 875
prodrugs 1667
profile 1237
progestagen 841
progesterone receptor 241
prognosis 306, 314, 474, 639, 801, 903, 986, 1030, 1101, 1118, 1384, 1409, 1904, 1914
prognostic 1155
prognostic and diagnostic marker 646
prognostic marker 104
prognostic value 1504
projections 1484
proliferation 970
proportional incidence method 1750
prospective studies 1139
prostate adenocarcinoma 269
prostate cancer 82, 137, 499, 523, 1384, 1475, 1587, 1595
prostate neoplasms 56
prostate tumours 352
prostate-specific antigen 56, 970
prostatic hyperplasia 980
prostatic intraepithelial neoplasia 1587
prostatic neoplasms 980
protection 1320
protein expression 269
proteomics 284
psychological; BRCA1/2 718
Pt-DNA adducts 231
PTHrP 1394
PTK6 (BRK) expression 801
quality assurance 157
quality of life 1834
R116010 1675
radiation 1439
radiation injury 1001
radioimmunotherapy 1862
radiosensitisation 1532
radiosensitivity 118
radiosensitizer 1650
radiotherapy 692, 708, 1183, 1442, 1871
RAMBAs 1204
randomised clinical trials 1170
randomised controlled trials 56, 1025
RAS 16
real-time polymerase chain reaction 783
rectal cancer 213, 1170
recurrence 1625, 1802
Recurrent glioblastoma 960
recurrent tumours 321
regulatory T cells 1849
relapse 732, 1147
relative risk 752
relative survival 1135
renal carcinoma 1284
renal cell carcinoma 567, 1888
reproduction 1450
reproductive factors 845
resveratrol 1595
retinoic acid 1204, 1675
RET/PTC oncogene 16
retrospective review 1802
RHPS4 1223
ribonucleotide reductase 457
rice bran 248
risk 1450
risk factors 1139, 1147
risk management 718
rituximab 1540
RKIP 1540
RNA interference 126
ROC curve analysis 793
role in cancer 417
S-1 277, 1353, 1650
salivary glands 1101
Salmonella typhimurium 758
salvage therapy 864
SCCHN 408
scid mouse 609
SCLC 886
scoring system 793
Scotland 818, 832, 1772
screening 140, 143, 218, 738, 868, 1107, 1335, 1750
SDF-1 485
SEC11L3 373
second-line therapy 1052
‘see and treat' 738
seminoma 529
senescence 1707
sensitivity 1750
sequential 1644
serine protease 362
serology 623
serum 1278
service users 875
sex of children 1433
sex ratio 1439
sibship size 1755
sigmoidoscopy 828
signal transduction 284
signalling transduction pathways 918
Singapore Chinese 821
single nucleotide polymorphism 783
SKOV-3 296
small cell 708
smoking 845, 1191
smoking cessation 1057
SN-38 21
SNP 499
socioeconomic background 836
socioeconomic deprivation 1760
socio-economic status 818
sonic hedgehog 1855
SOX2 1293
specificity 56
spheroids 1072
sputum 1278
squamous cell carcinoma 519, 952, 1234
stage at diagnosis 836
stage III NSCLC 1498
staging investigations 882
standardised incidence ratio 1475
Stat3 591
stem cells 6, 1020, 1223
stomach neoplasms 1514
stool test 1329
streptozotocin 49
subcellular localisation 944
suicide 752
sulphamates 1368
sunlight exposure 832
superior sulcus tumour 1498
surgery 262, 1025
surrogate marker 284
survival 213, 222, 519, 529, 836, 891, 1083, 1147, 1462, 1772, 1796, 1802, 1817, 1834
survival analysis 1030
survivin 639
survivin-ΔEx3 1659
Sweden 519
systematic review 226, 391
systemic inflammatory response 891
T cells 1839
tamoxifen 850, 1025
targeted intervention 162
targeted therapy 1520
TAS-102 61
Taxol 1223
technician 744
teenage and young adult cancer 1760
tegafur–uracil 38
telangiectasia 1001
telomerase 1020, 1223
telomere 1020, 1223, 1908
temozolomide 44, 864, 960
temsirolimus 952
testicular cancer 357, 529
testicular seminoma 882
tetracyclines 1526
TGF-β 1560
TGFβ1 1001
TGFβ2 immunosuppression 1879
therapeutic monitoring 725
thymidylate synthase 277, 769
thyroid 1237, 1549
TIMP 903
tissue arrays 903
tissue factor 290
tissue microarray 82, 329, 485, 591, 776, 793
tissue microdissection 373
tolerogenic dendritic cell 1879
tomography 1030
topoisomerase II 201
toxicity 701
TP53 336
transcription 1284, 1394
transforming growth factor- alpha 1569
translation elongation 1613
trastuzumab 654, 1520
treatment 836, 1197, 1834
Treg 617
trends 1135, 1743
trial 1796
trifluorothymidine 231
trifunctional antibodies 1013
trimodality 1498
tubulin 1684
tumour 6, 1278, 1862
tumour characteristics 1197
tumour escape 980
tumour hypoxia 1871
tumour immunity 1839
tumour infiltrating lymphocytes 617
tumour location 1324
tumour M2-PK 1329
tumour marker 623, 681
tumour vascularisation 49
tumoural invasion 903
tumour-associated antigen 567, 1293
tumour-targeted superantigen 567
TUNEL 1101
TVU 1335
Twist 314
type 1419
tyrosine kinase inhibitor 408
TZT-1027 1532
UFT 38, 439, 1170
ultraviolet radiation 523
urinary 5-hydroxyindoleacetic acid 1178
urokinase plasminogen activator (u-PA) 262
uterine cervical cancer 1735
uterine cervical neoplasms 1057
vaccination 143, 514
vaccines 1320
validation 1155
valproic acid 1699
vascular disrupting drugs 1159
vascular endothelial cell growth factors 1092
vascular endothelial growth factor receptor-1 1723
vasculature 1862
VEGF 776, 1377, 1735
VEGF signalling 1788
VEGF-A 1092
VEGF-C 541, 1092
VEGF-D 1092
VEGFR-3 541
venous thromboembolism 290
Versican 1560
vimentin 986
vinorelbine 1052, 1633
viral load 1554
von Hippel–Lindau 1284
waiting times 162
WHO classification 1178
women 1135
WTH3 gene 1579
WXC-340 262
xenograft human tumour 758
X-ray computed 1030
XRCC1 1001
Y chromosome 357
young patients 1743
young-onset diabetes 507
Zambia 1480
zoledronic acid 255
zyxin 296
